PART I A. Overview We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb drug candidates with improved properties and multi-target mechanisms of action. We advance these candidates into clinical-stage development, where we are conducting Phase 1 and Phase 2 studies fo...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001326732-26-000015 | EDGAR | 77K words |
| 2025-02-27 | 2024-12-31 | 0001326732-25-000029 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001326732-24-000006 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0001628280-23-005127 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001558370-22-001969 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001558370-21-001522 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001558370-20-001256 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001558370-19-001049 | EDGAR | — |
| 2018-02-28 | 2017-12-31 | 0001558370-18-001202 | EDGAR | — |
| 2017-03-01 | 2016-12-31 | 0001558370-17-001196 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001326732-26-000056 | EDGAR | — |
| 2025-11-05 | 2025-09-30 | 0001326732-25-000087 | EDGAR | 22K words |
| 2025-08-06 | 2025-06-30 | 0001326732-25-000075 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001326732-25-000053 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001326732-24-000060 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0001326732-24-000043 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001326732-24-000029 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001326732-23-000042 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0001326732-23-000026 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0001628280-23-016494 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001558370-22-016660 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001558370-22-011923 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0001326732-26-000055 | EDGAR | — |
| 2026-07-29 | 0001326732-26-000049 | EDGAR | — |
| 2026-03-09 | 0001326732-26-000023 | EDGAR | 1K words |
| 2026-03-04 | 0001326732-26-000021 | EDGAR | — |
| 2026-02-25 | 0001326732-26-000014 | EDGAR | — |
| 2026-01-08 | 0001326732-26-000002 | EDGAR | — |
| 2025-11-05 | 0001326732-25-000086 | EDGAR | — |
| 2025-10-24 | 0001326732-25-000082 | EDGAR | — |
| 2025-08-06 | 0001326732-25-000074 | EDGAR | — |
| 2025-07-31 | 0001326732-25-000063 | EDGAR | — |
214 total filings indexed. 182 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001326732 |
| Ticker | XNCR |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.xencor.com |
| Listed | 2013-12-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/XNCR (~200 tokens, structured JSON with cryptographic provenance)